Clinical Trials Sponsored by Geneplus-Beijing Co. Ltd.

Total 785 results

Geneplus-Beijing Co. Ltd.

Not yet recruiting

The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer

Ovarian Cancer

China
Geneplus-Beijing Co. Ltd.

Recruiting

Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Lung Cancer

China
Geneplus-Beijing Co. Ltd.

Recruiting

A Biomarker Study for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients

Colorectal Cancer

China
Geneplus-Beijing Co. Ltd.
Xuanwu Hospital, Beijing

Unknown

The Tracking Molecular Evolution for NSCLC (T-MENC) Study

Lung Neoplasms | Lung Cancer | Adenocarcinoma of Lung | Nonsmall Cell Lung Cancer

China
Sichuan University
Geneplus-Beijing Co. Ltd.

Recruiting

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Non-small Cell Lung Cancer

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Geneplus-Beijing Co. Ltd.
Shanghai Chest Hospital

Completed

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Lung Neoplasms | Adenocarcinoma of Lung | Lung Cancer, Nonsmall Cell | Squamous Cell Lung Cancer

China
Geneplus-Beijing Co. Ltd.
Shanghai Chest Hospital

Recruiting

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Lung Neoplasms | Adenocarcinoma of Lung | Lung Cancer, Nonsmall Cell | Squamous Cell Lung Cancer

China
Geneplus-Beijing Co. Ltd.
Beijing Hospital; Emergency General Hospital

Recruiting

Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)

Pulmonary Nodule, Solitary | Whole-genome Methylation Sequencing

China
Geneplus-Beijing Co. Ltd.
Eastern Hepatobiliary Surgery Hospital

Withdrawn

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Hepatocellular Carcinoma | Primary Liver Cancer | Intrahepatic Cholangiocarcinoma | Combined Hepatocellular-cholangiocarcinoma

China
Geneplus-Beijing Co. Ltd.
Chinese PLA General Hospital

Recruiting

The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor

Early Detection of Cancer

China
Geneplus-Beijing Co. Ltd.
Army Medical University, China

Recruiting

ctDNA Monitoring in Early Breast Cancer

Breast Cancer

China
Capital Medical University
Duke University; Geneplus-Beijing Co. Ltd.

Completed

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Neoplasms | Lung Cancer

China
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
Peking Union Medical College Hospital
Geneplus-Beijing Co. Ltd.

Active, not recruiting

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Biliary Tract Cancer | Predictive Cancer Model | Immune Checkpoint Inhibitor

China
Peking Union Medical College Hospital
Geneplus-Beijing Co. Ltd.

Unknown

Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

Rectal Cancer, Adenocarcinoma | Neoadjuvant Chemoradiation
Geneplus-Beijing Co. Ltd.
Peking Union Medical College Hospital

Active, not recruiting

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Ovarian Cancer

China
Capital Medical University
Duke University; Geneplus-Beijing Co. Ltd.

Completed

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

Gastric Cancer

China
The First Hospital of Jilin University
Geneplus-Beijing Co. Ltd.

Recruiting

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Endometrial Cancer

China
Second Xiangya Hospital of Central South University
Geneplus-Beijing Co. Ltd.

Not yet recruiting

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
GeneCast Biotechnology Co., Ltd.; Geneplus-Beijing Co. Ltd.; OrigiMed; YuceBio...

Recruiting

Hepatobiliary Tumors Tissue Samples Acquisition

Hepatocellular Carcinoma | Cholangiocarcinoma | Precancerous Condition | Liver Cancer | Biliary Tract Cancer | Gallbladder Cancer | Healthy, no Evidence of Disease | Benign Hepatobiliary Disease

China
Beijing Kejing Biotechnology Co., Ltd.
Beijing Kejing Biotechnology Corp.

Withdrawn

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients (CCT-ANK-11)

Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
First Affiliated Hospital of Zhejiang University
Hoffmann-La Roche; Geneplus-Beijing Co. Ltd.

Unknown

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Non-Small Cell Lung Cancer

China
Shanghai Chest Hospital
Geneplus-Beijing Co. Ltd.; Guangzhou Burning Rock Medical Examination Institute... and other collaborators

Unknown

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

NSCLC | Malignant Hydrothorax

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Active, not recruiting

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

COVID-19 Pneumonia

Spain, Bangladesh, China, India, Indonesia
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Completed

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrei Biotechnology Co.,Ltd

Completed

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

Healthy

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrei Biotechnology Co.,Ltd

Completed

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

Healthy

China
Beijing Syngentech Co., Ltd.

Not yet recruiting

SynOV1.1 Intratumoral Injection Study

Hepatocellular Carcinoma
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Beijing VDJBio Co., LTD.

Completed

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Rheumatoid Arthritis

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Novikang Medical Technology Co., LTD

Completed

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Hemophilia

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Sanuo Jiayi Biotechnology Co. LTD

Terminated

To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Sanuo Jiayi Biotechnology Co. LTD

Terminated

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
Beijing Pins Medical Co., Ltd
Beijing Hospital

Unknown

Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)

Refractory Overactive Bladder

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects

Health Subjects

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation

Atrial Fibrillation
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Type2 Diabetes Mellitus

China
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus

China
Beijing Tide Pharmaceutical Co., Ltd

Not yet recruiting

A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough

Refractory Chronic Cough
Beijing Luzhu Biotechnology Co., Ltd.

Recruiting

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Herpes Zoster | Vaccine-Preventable Diseases

China
Beijing Airdoc Technology Co., Ltd.

Recruiting

Myopia Preventing With Distance-image Screen (DIS)

Myopia, Progressive

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Beijing Tide Pharmaceutical Co., Ltd

Recruiting

A Phase I/II Clinical Study in Patients With Advanced Solid Tumor.

Patients With Advanced Solid Tumors

China
Axter Therapeutics (Beijing) Co., Ltd

Recruiting

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Primary Membranous Nephropathy

China

Clinical Trials Sponsored by Geneplus-Beijing Co. Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations